Zobrazeno 1 - 10
of 60
pro vyhledávání: '"Mounir Ait‐Khaled"'
Autor:
Cassidy A. Gutner PhD, Marc van der Valk MD, PhD, Joaquin Portilla MD, Eliette Jeanmaire MD, Leïla Belkhir MD, PhD, Thomas Lutz MD, Rebecca DeMoor MSc, Rekha Trehan BSc, Jenny Scherzer MBA, MSc, Miguel Pascual-Bernáldez PharmB, Mounir Ait-Khaled PhD, Beatriz Hernandez PharmD, PhD, Annemiek de Ruiter MBBS, FRCP, Savita Bakhshi Anand PhD, Emma L. Low PhD, Monica Hadi PhD, Nicola Barnes MA, Nick Sevdalis PhD, Perry Mohammed MBBS, Maggie Czarnogorski MD, MPH
Publikováno v:
Journal of the International Association of Providers of AIDS Care, Vol 23 (2024)
Introduction CARISEL is an implementation–effectiveness “hybrid” study examining the perspectives of people living with HIV-1 (patient study participants [PSPs]) on cabotegravir (CAB) plus rilpivirine (RPV) long-acting (LA) dosed every 2 months
Externí odkaz:
https://doaj.org/article/5d90730f2456430790ded91fab079d5b
Autor:
Sharon Walmsley, Don E. Smith, Miguel Górgolas, Pedro E. Cahn, Thomas Lutz, Karine Lacombe, Princy N. Kumar, Brian Wynne, Richard Grove, Gilda Bontempo, Riya Moodley, Chinyere Okoli, Michelle Kisare, Bryn Jones, Andrew Clark, Mounir Ait-Khaled
Publikováno v:
AIDS Research and Therapy, Vol 21, Iss 1, Pp 1-9 (2024)
Abstract Background As the population of people with HIV ages, concerns over managing age-related comorbidities, polypharmacy, immune recovery, and drug-drug interactions while maintaining viral suppression have arisen. We present pooled TANGO and SA
Externí odkaz:
https://doaj.org/article/7b821da8aae94b9ea95b9b1b7ced2c3e
Autor:
Cassidy A. Gutner, Laurent Hocqueloux, Celia Jonsson‐Oldenbüttel, Linos Vandekerckhove, Berend J. vanWelzen, Laurence Slama, María Crusells‐Canales, Julián Olalla Sierra, Rebecca DeMoor, Jenny Scherzer, Mounir Ait‐Khaled, Gilda Bontempo, Martin Gill, Natasha Patel, Ronald D'Amico, Kai Hove, Bryan Baugh, Nicola Barnes, Monica Hadi, Emma L. Low, Savita Bakhshi Anand, Alison Hamilton, Harmony P. Garges, Maggie Czarnogorski
Publikováno v:
Journal of the International AIDS Society, Vol 27, Iss 7, Pp n/a-n/a (2024)
Abstract Introduction Cabotegravir plus rilpivirine (CAB + RPV) is the first complete long‐acting (LA) regimen recommended for maintaining HIV‐1 virological suppression. Cabotegravir And Rilpivirine Implementation Study in European Locations (CAR
Externí odkaz:
https://doaj.org/article/cf663c19fbc04c13b44fe74a60666e97
Autor:
Mounir Ait-Khaled, Juan Sierra Madero, Vicente Estrada, Roberto Gulminetti, Debbie Hagins, Hung-Chin Tsai, Choy Man, Jörg Sievers, Richard Grove, Andrew Zolopa, Brian Wynne, Jean van Wyk
Publikováno v:
HIV Research & Clinical Practice, Vol 23, Iss 1, Pp 9-14 (2021)
Background: GEMINI-1 and GEMINI-2 (ClinicalTrials.gov, NCT02831673 and NCT02831764, respectively) are double-blind, multicenter, phase III studies that demonstrated the non-inferiority of once-daily dolutegravir + lamivudine to dolutegravir + tenofov
Externí odkaz:
https://doaj.org/article/5ba59213feaa4f1abb8a36a2726d56ec
Autor:
Ruolan Wang, Jonathan Wright, Parminder Saggu, Mounir Ait-Khaled, Riya Moodley, Chris M. Parry, Thomas Lutz, Daniel Podzamczer, Richard Moore, Miguel Górgolas Hernández-Mora, Clifford Kinder, Brian Wynne, Jean van Wyk, Mark Underwood
Publikováno v:
Viruses, Vol 15, Iss 6, p 1350 (2023)
The TANGO study (ClinicalTrials.gov, NCT03446573) demonstrated that switching to dolutegravir/lamivudine (DTG/3TC) was non-inferior to continuing tenofovir alafenamide-based regimens (TBR) through week 144. Retrospective baseline proviral DNA genotyp
Externí odkaz:
https://doaj.org/article/ea428c0f0de44faeb940da0a4b8c9914
Autor:
Olayemi Osiyemi, Faïza Ajana, Fiona Bisshop, Stéphane de Wit, Joaquín Portilla, Jean-pierre Routy, Christoph Wyen, Mounir Ait-khaled, Keith A. Pappa, Ruolan Wang, Peter A. Leone, Jonathan Wright, Brian Wynne, Jean van Wyk, Michael Aboud, Kimberly Y. Smith
Publikováno v:
Brazilian Journal of Infectious Diseases, Vol 26, Iss , Pp 101719- (2022)
Dolutegravir/Lamivudina (DTG / 3TC) é um regime completo de 2 medicamentos (2DR) para o tratamento do HIV-1. A eficácia virológica não inferior foi comprovada ao longo de 3 anos em pessoas virgens de tratamento PARA HIV e 2 anos em um ambiente de
Externí odkaz:
https://doaj.org/article/01fdfbecdd6f4cadb4cf52a1762b3b8b
Autor:
Jean Van Wyk, Faïza Ajana, Fiona Bisshop, Stéphane de Wit, Mounir Ait‐Khaled, Ruolan Wang, Jonathan Wright, Michael Aboud, Kimberly Smith, Roberto Zajdenverg
Publikováno v:
Brazilian Journal of Infectious Diseases, Vol 25, Iss , Pp 101258- (2021)
Externí odkaz:
https://doaj.org/article/bcc40a120fcb4629b87cfb73f29ea086
Autor:
Olayemi, Osiyemi, Stéphane, De Wit, Faïza, Ajana, Fiona, Bisshop, Joaquín, Portilla, Jean Pierre, Routy, Christoph, Wyen, Mounir, Ait-Khaled, Peter, Leone, Keith A, Pappa, Ruolan, Wang, Jonathan, Wright, Nisha, George, Brian, Wynne, Michael, Aboud, Jean, van Wyk, Kimberly Y, Smith
Publikováno v:
Clinical Infectious Diseases. 75:975-986
Background Switching to dolutegravir/lamivudine (DTG/3TC) was noninferior to continuing tenofovir alafenamide (TAF)–based regimens for maintaining virologic suppression at week 48 of the TANGO study. Here we present week 144 outcomes (efficacy, saf
Autor:
Manyu Prakash, Richard Grove, Brian R Wynne, Choy Man, Jean A van Wyk, Clifford B Jones, Chinyere Okoli, Emilio Letang, Mounir Ait-Khaled, Andrew Clark
Publikováno v:
Open Forum Infectious Diseases. 9
Background The proportion of older adults living with HIV is growing, increasing the focus of managing age-related comorbidities and polypharmacy while maintaining virologic suppression. DTG/3TC is an international guidelines–recommended 2-drug reg
Autor:
Stephane De Wit, Agathe Rami, Fabrice Bonnet, Rebecca DeMoor, Gilda Bontempo, Christine Latham, Martin Gill, Monica Hadi, Owen Cooper, Savita Bakhshi Anand, Cassidy Gutner, Mounir Ait-Khaled, Jean A van Wyk, Maggie Czarnogorski
Publikováno v:
Open Forum Infectious Diseases. 9
Background Cabotegravir + Rilpivirine Long Acting (CAB+RPV LA) every 2 months is a recommended regimen in European and US treatment guidelines for PLWH with virological suppression and no known resistance to CAB or RPV. CARISEL, an implementation stu